W. Cliff Rutter

520 total citations
24 papers, 402 citations indexed

About

W. Cliff Rutter is a scholar working on Pharmacology, Infectious Diseases and Nephrology. According to data from OpenAlex, W. Cliff Rutter has authored 24 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pharmacology, 8 papers in Infectious Diseases and 6 papers in Nephrology. Recurrent topics in W. Cliff Rutter's work include Antibiotics Pharmacokinetics and Efficacy (17 papers), Antimicrobial Resistance in Staphylococcus (8 papers) and Acute Kidney Injury Research (6 papers). W. Cliff Rutter is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (17 papers), Antimicrobial Resistance in Staphylococcus (8 papers) and Acute Kidney Injury Research (6 papers). W. Cliff Rutter collaborates with scholars based in United States. W. Cliff Rutter's co-authors include David S. Burgess, Donna R. Burgess, Craig A. Martin, Jeffery Talbert, Ryan L. Crass, Ronald G. Hall, Grace C. Lee, David J. Feola, Andrew Redd and Jud C. Janak and has published in prestigious journals such as The Lancet, Blood and Annals of Surgery.

In The Last Decade

W. Cliff Rutter

21 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W. Cliff Rutter United States 11 255 144 126 115 90 24 402
Cruz Soriano Spain 12 97 0.4× 117 0.8× 199 1.6× 148 1.3× 140 1.6× 22 559
Evelyn Dhont Belgium 9 231 0.9× 55 0.4× 124 1.0× 64 0.6× 42 0.5× 30 340
Madiha Salim United States 6 234 0.9× 150 1.0× 131 1.0× 88 0.8× 204 2.3× 10 422
Bhagyashri Navalkele United States 10 160 0.6× 278 1.9× 202 1.6× 98 0.9× 19 0.2× 21 459
Joseph J. Carreno United States 13 142 0.6× 159 1.1× 125 1.0× 37 0.3× 46 0.5× 22 369
Konstantinos N. Fragoulis Greece 7 101 0.4× 77 0.5× 111 0.9× 31 0.3× 128 1.4× 11 337
Helmi Sulaiman Malaysia 8 216 0.8× 90 0.6× 185 1.5× 15 0.1× 115 1.3× 32 493
Laurie B. Hovde United States 13 350 1.4× 104 0.7× 174 1.4× 28 0.2× 313 3.5× 24 527
D. Matthew Shoemaker United States 5 176 0.7× 74 0.5× 86 0.7× 54 0.5× 61 0.7× 10 301
Ana Maria Sandri Brazil 10 340 1.3× 119 0.8× 259 2.1× 25 0.2× 410 4.6× 11 613

Countries citing papers authored by W. Cliff Rutter

Since Specialization
Citations

This map shows the geographic impact of W. Cliff Rutter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Cliff Rutter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Cliff Rutter more than expected).

Fields of papers citing papers by W. Cliff Rutter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Cliff Rutter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Cliff Rutter. The network helps show where W. Cliff Rutter may publish in the future.

Co-authorship network of co-authors of W. Cliff Rutter

This figure shows the co-authorship network connecting the top 25 collaborators of W. Cliff Rutter. A scholar is included among the top collaborators of W. Cliff Rutter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Cliff Rutter. W. Cliff Rutter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Beyer, Carl A., Eduard Poltavskiy, Lauren Walker, et al.. (2019). Persistent Opioid Use After Combat Injury and Subsequent Long-term Risk of Abuse. Annals of Surgery. 274(6). e957–e965. 15 indexed citations
2.
Rutter, W. Cliff, Ronald G. Hall, & David S. Burgess. (2019). Impact of total body weight on rate of acute kidney injury in patients treated with piperacillin–tazobactam and vancomycin. American Journal of Health-System Pharmacy. 76(16). 1211–1217. 11 indexed citations
3.
Rutter, W. Cliff, et al.. (2018). Effect of increasing meropenem MIC on the killing activity of meropenem in combination with amikacin or polymyxin B against MBL- and KPC-producing Enterobacter cloacae. Diagnostic Microbiology and Infectious Disease. 92(3). 262–266. 20 indexed citations
4.
Rutter, W. Cliff & David S. Burgess. (2018). Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin. Antimicrobial Agents and Chemotherapy. 62(7). 50 indexed citations
5.
Rutter, W. Cliff, Donna R. Burgess, Jeffery Talbert, & David S. Burgess. (2017). Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin‐Tazobactam: A Retrospective Cohort Analysis. Journal of Hospital Medicine. 12(2). 77–82. 53 indexed citations
6.
Crass, Ryan L., W. Cliff Rutter, Donna R. Burgess, Craig A. Martin, & David S. Burgess. (2017). Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin. Antimicrobial Agents and Chemotherapy. 61(4). 33 indexed citations
7.
Rutter, W. Cliff, et al.. (2017). Influence of β-Lactam Infusion Strategy on Acute Kidney Injury. Antimicrobial Agents and Chemotherapy. 61(10). 28 indexed citations
8.
Rutter, W. Cliff & David S. Burgess. (2017). Acute Kidney Injury in Patients Treated with IV Beta‐Lactam/Beta‐Lactamase Inhibitor Combinations. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 37(5). 593–598. 21 indexed citations
9.
Rutter, W. Cliff & David S. Burgess. (2017). Is There a Significant Difference in Acute Kidney Injury Incidence Among Patients Treated with Vancomycin Combined with Cefepime or Meropenem?. Open Forum Infectious Diseases. 4(suppl_1). S338–S338.
10.
Rutter, W. Cliff, et al.. (2016). Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Bacterial Isolates. Microbial Drug Resistance. 23(1). 51–55. 48 indexed citations
11.
Martin, Craig A., et al.. (2016). Optimizing beta-lactam pharmacodynamics against Pseudomonas aeruginosa in adult cystic fibrosis patients. Journal of Cystic Fibrosis. 15(5). 660–663. 11 indexed citations
12.
Rutter, W. Cliff & David S. Burgess. (2016). Nephrotoxicity and Clinical Outcomes in Patients Treated With Nafcillin or Cefazolin. Open Forum Infectious Diseases. 3(suppl_1). 1 indexed citations
13.
Rutter, W. Cliff & David S. Burgess. (2016). Comparative Rates of Nephrotoxicity in Patients Treated With Piperacillin-Tazobactam and Meropenem: A Retrospective Cohort Study.. Open Forum Infectious Diseases. 3(suppl_1). 1 indexed citations
14.
Rutter, W. Cliff, et al.. (2016). Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime. Antimicrobial Agents and Chemotherapy. 61(2). 94 indexed citations
15.
Rutter, W. Cliff, et al.. (2016). Influence of Beta-Lactam Infusion Strategy on Acute Kidney Injury. Open Forum Infectious Diseases. 3(suppl_1). 3 indexed citations
16.
Rutter, W. Cliff, et al.. (2015). Acute Kidney Injury During Therapy With Vancomycin in Combination With β-Lactams. Open Forum Infectious Diseases. 2(suppl_1).
17.
Rutter, W. Cliff, Jeffery Talbert, & David S. Burgess. (2015). Factors Associated With Supratherapeutic Vancomycin Trough Concentrations in a Referral Center. Open Forum Infectious Diseases. 2(suppl_1). 1 indexed citations
18.
Rutter, W. Cliff, Donna R. Burgess, & David S. Burgess. (2015). Increasing Incidence of Multidrug Resistance Among Cystic Fibrosis Respiratory Isolates. Open Forum Infectious Diseases. 2(suppl_1). 1 indexed citations
19.
Rutter, W. Cliff, Jeffery Talbert, & David S. Burgess. (2015). Incidence of Acute Kidney Injury in Patients Treated With Vancomycin and Piperacillin/Tazobactam. Open Forum Infectious Diseases. 2(suppl_1). 1 indexed citations
20.
Fudenberg, H. Hugh, et al.. (1974). BIOASSAYS OF CYSTIC-FIBROSIS FACTOR. The Lancet. 303(7854). 404–405. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cruz Soriano Breakdown of academic impact, for papers by Evelyn Dhont Breakdown of academic impact, for papers by Madiha Salim Breakdown of academic impact, for papers by Bhagyashri Navalkele Breakdown of academic impact, for papers by Joseph J. Carreno Breakdown of academic impact, for papers by Konstantinos N. Fragoulis Breakdown of academic impact, for papers by Helmi Sulaiman Breakdown of academic impact, for papers by Laurie B. Hovde Breakdown of academic impact, for papers by D. Matthew Shoemaker Breakdown of academic impact, for papers by Ana Maria Sandri
Rankless by CCL
2026